CERo Therapeutics (CERO) News Mentions Statistics 2024

00%

1W 0%

Est. daily news mentions.

Similar companies

Company		News Mentions
	Amgen AMGN	0 0%
	Gilead Sciences GILD	2 0%
	Catalyst Pharmaceuticals CPRX	0 0%
	Inovio Pharmaceuticals INO	0 100%
	Anavex Life Sciences AVXL	0 0%

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

November 14

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

November 10

How often is CERo Therapeutics mentioned in the news?

CERo Therapeutics was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is CERo Therapeutics performing compared to its industry peers?

CERo Therapeutics underperforms its industry peers when it comes to News Mentions, ranking dead last.

Why is it important to track news mentions for CERo Therapeutics?

By monitoring mentions in the news for CERo Therapeutics, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of CERo Therapeutics, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.